215 related articles for article (PubMed ID: 32205533)
1. Prognostic and Predictive Biomarkers in Oligometastatic Disease.
Barnum KJ; Weiss SA
Cancer J; 2020; 26(2):100-107. PubMed ID: 32205533
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
3. Treatment Strategies for Oligometastatic Breast Cancer.
Nesbit EG; Donnelly ED; Strauss JB
Curr Treat Options Oncol; 2021 Aug; 22(10):94. PubMed ID: 34426881
[TBL] [Abstract][Full Text] [Related]
4. Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective.
Hafez N; Gettinger S
Cancer J; 2020; 26(2):144-148. PubMed ID: 32205539
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis.
Routman DM; Chera BS; Gupta GP
Cancer J; 2020; 26(2):116-123. PubMed ID: 32205535
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
Olson R; Mathews L; Liu M; Schellenberg D; Mou B; Berrang T; Harrow S; Correa RJM; Bhat V; Pai H; Mohamed I; Miller S; Schneiders F; Laba J; Wilke D; Senthi S; Louie AV; Swaminath A; Chalmers A; Gaede S; Warner A; de Gruijl TD; Allan A; Palma DA
BMC Cancer; 2020 May; 20(1):380. PubMed ID: 32370765
[TBL] [Abstract][Full Text] [Related]
7. Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease.
Foster CC; Pitroda SP; Weichselbaum RR
Cancer J; 2020; 26(2):96-99. PubMed ID: 32205532
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management.
Correa RJ; Salama JK; Milano MT; Palma DA
Cancer J; 2016; 22(4):247-56. PubMed ID: 27441744
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
10. Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy.
Nakamura M; Kageyama SI; Seki M; Suzuki A; Okumura M; Hojo H; Motegi A; Akimoto T
Anticancer Res; 2021 Feb; 41(2):829-834. PubMed ID: 33517288
[TBL] [Abstract][Full Text] [Related]
11. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.
Niazi T; Elakshar S; Stroian G
Curr Opin Support Palliat Care; 2018 Sep; 12(3):351-358. PubMed ID: 29979320
[TBL] [Abstract][Full Text] [Related]
12. New Strategies in Stereotactic Radiotherapy for Oligometastases.
Palma DA; Louie AV; Rodrigues GB
Clin Cancer Res; 2015 Dec; 21(23):5198-204. PubMed ID: 26626571
[TBL] [Abstract][Full Text] [Related]
13. The utilization of circulating tumor DNA to predict the risk and location of relapse after curative-intent local therapy in oligometastatic colorectal cancer.
Radomski SN; Ali S; Lafaro KJ; Shubert C; Hidalgo M; Chung H; Christenson ES
J Gastrointest Surg; 2024 Apr; 28(4):534-537. PubMed ID: 38583907
[No Abstract] [Full Text] [Related]
14. [Oligometastases and oligoprogressions: Concepts and natural history].
Annede P; Chargari C
Cancer Radiother; 2019 Oct; 23(6-7):475-481. PubMed ID: 31447345
[TBL] [Abstract][Full Text] [Related]
15. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Jairam V; Park HS; Decker RH
Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
[TBL] [Abstract][Full Text] [Related]
16. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT).
Wong AC; Watson SP; Pitroda SP; Son CH; Das LC; Stack ME; Uppal A; Oshima G; Khodarev NN; Salama JK; Weichselbaum RR; Chmura SJ
Cancer; 2016 Jul; 122(14):2242-50. PubMed ID: 27206146
[TBL] [Abstract][Full Text] [Related]
18. Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer.
Shirasawa M; Fukui T; Kusuhara S; Harada S; Nishinarita N; Hiyoshi Y; Ishihara M; Kasajima M; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
PLoS One; 2019; 14(4):e0214599. PubMed ID: 31002722
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
20. Blood-based tumour mutational burden analysis in NSCLC.
Das M
Lancet Oncol; 2018 Sep; 19(9):e446. PubMed ID: 30122616
[No Abstract] [Full Text] [Related]
[Next] [New Search]
